BPR1K871 is primarily investigated for its potential in cancer therapy, particularly as a kinase inhibitor. It targets specific signaling pathways involved in tumor growth and proliferation, making it a promising candidate for treating various cancers. Researchers are exploring its efficacy in inhibiting abnormal cell division and inducing apoptosis in cancer cells. Additionally, it is being studied in combination therapies to enhance the effectiveness of existing treatments. Its application extends to preclinical and early clinical trials, focusing on its safety, pharmacokinetics, and therapeutic potential in oncology.